Truist Securities maintains Buy rating on Arcus Biosciences, $41 price target

Truist Securities maintained their Buy rating on Arcus Biosciences's stock with a price target of $41.00.

The price target implies an upside of 72.6% from the Oct 20 close of $23.75.

Key takeaways from the analyst note

Strong Clinical Data: Arcus Biosciences is supported by promising clinical results, particularly with the efficacy of its product candidates like Cas + Cabo, which demonstrates a competitive edge in overall survival and progression-free survival compared to existing therapies, suggesting potential for market differentiation.

Expanding Pipeline and Market Opportunity: The company has a robust pipeline with multiple Phase III programs planned, indicating a strong potential for revenue growth, estimated to reach ~$3.2 billion. This potential, combined with a favorable setup for upcoming trials, reinforces confidence in its stock.

Explore more price target data and ratings for Arcus Biosciences on the .